- Home
- CCEC vs KARD Comparison
CCEC vs KARD Comparison
Compare CCEC & KARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CCEC | KARD |
|---|---|---|
| Founded | 2007 | 2023 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 2007 | 2026 |
Fundamental Metrics
Financial Performance| Metric | CCEC | KARD |
|---|---|---|
| Price | $20.20 | $12.63 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 6 |
| Target Price | $25.83 | ★ $38.67 |
| AVG Volume (30 Days) | 5.9K | ★ 609.2K |
| Earning Date | 11-02-2026 | 11-22-2026 |
| Dividend Yield | ★ 3.03% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $19.18 | N/A |
| Revenue Next Year | $36.89 | $50.00 |
| P/E Ratio | $4.82 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.77 | $12.23 |
| 52 Week High | $23.95 | $27.00 |
Technical Indicators
Market Signals| Indicator | CCEC | KARD |
|---|---|---|
| Relative Strength Index (RSI) | 43.51 | 35.12 |
| Support Level | $19.98 | $12.23 |
| Resistance Level | $21.36 | $15.93 |
| Average True Range (ATR) | 0.45 | 1.36 |
| MACD | -0.02 | 0.08 |
| Stochastic Oscillator | 41.71 | 10.95 |
Price Performance
Historical ComparisonAbout CCEC Capital Clean Energy Carriers Corp.
Capital Clean Energy Carriers Corp is an international shipping company. It is the platform of gas carriage solutions with a focus on the energy transition. The company owns 20 high-specification vessels, including 12 latest-generation LNG carriers (LNG/Cs) and eight legacy Neo-Panamax container vessels.
About KARD Kardigan Inc. Common Stock
Kardigan Inc is a clinical-stage therapeutics company focused on developing medicines for cardiovascular diseases. Its activities include the research and development of targeted therapies for cardiovascular conditions for which no approved treatments currently exist. The company's clinical-stage programs include Danicamtiv, Ataciguat, and Tonlamarsen, which are being developed for cardiovascular disease indications. The company operates and manages its business as a single operating and reportable segment, focused on the discovery and development of novel therapeutic products to treat cardiovascular disease.